Survodutide 10mg

Survodutide 10 mg research material

Buy Survodutide 10 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.

Survodutide, known as BI 456906 in development studies, is a modified peptide investigated at glucagon and GLP-1 receptors.

One analog with two receptor targets

Survodutide is a dual-receptor analog, not a two-ingredient peptide blend. Its 10 mg label refers to the named compound rather than separate amounts assigned to each receptor target.

Mazdutide 10 mg has overlapping receptor-research context but is a different molecule. Matching milligrams or counting receptor targets does not establish equivalent potency. Choose the analog specified by the experimental method and verify the supplied form.

How BI 456906 was characterized

In Zimmermann and colleagues’ original preclinical study, investigators examined functional receptor activity using cell-based assays, including cAMP responses, and studied target engagement in mouse models.

The work assessed glucagon-receptor and GLP-1-receptor responses separately. This distinction matters when evaluating a dual agonist: activity at one receptor is not sufficient evidence of the full two-receptor profile.

The published results concern the authors’ defined study material and experimental systems. They do not certify the identity or potency of a commercial lot, or establish clinical effects for the powder supplied here.

Review the batch report and product files

Open COA & Documents and match the product and lot. Review which methods address identity, chromatographic purity and measured content. A purity percentage is not a functional receptor assay and should not be read as a potency comparison with another analog.

Use formulation-specific records for storage and laboratory handling. The vial’s 3 mL capacity is separate from the 10 mg label; it does not describe liquid supplied or dictate a preparation volume.